Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Leveraging Artificial Intelligence in Drug and Biological Product Development: An FDA and Clinical Trial Transformation Initiative Workshop Report
0
Zitationen
9
Autoren
2025
Jahr
Abstract
Artificial intelligence (AI) holds immense potential to transform drug development by improving the efficiency and accuracy of key processes across the drug product life cycle. However, the scalable adoption of this technology may be influenced by new and unique challenges. The U.S. Food and Drug Administration collaborated with the Clinical Trial Transformation Initiative to organize a public workshop on Artificial Intelligence in Drug and Biological Product Development in August 2024 with medical product sponsors, technology innovators, academicians, and regulators to discuss guiding principles for the use of AI in drug and biological product development in order to realize its transformative potential. This article synthesizes key insights from the workshop and discusses the emerging current need for policy development to enhance the integration of AI in drug and biological product development.
Ähnliche Arbeiten
Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI
2019 · 8.200 Zit.
Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead
2019 · 8.051 Zit.
High-performance medicine: the convergence of human and artificial intelligence
2018 · 7.416 Zit.
Proceedings of the 19th International Joint Conference on Artificial Intelligence
2005 · 5.776 Zit.
Peeking Inside the Black-Box: A Survey on Explainable Artificial Intelligence (XAI)
2018 · 5.410 Zit.